Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FBRX NASDAQ:INZY NASDAQ:SCPH NYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBRXForte Biosciences$11.07+0.2%$11.12$4.11▼$28.68$137.60M2.6963,908 shs56,913 shsINZYInozyme Pharma$4.00$3.99$0.72▼$6.24$258.25M2.27960,267 shsN/ASCPHscPharmaceuticals$5.52+0.2%$4.81$1.94▼$6.28$294.21M0.35598,155 shs933,208 shsVORVor Biopharma$2.00-2.0%$2.03$0.13▼$3.29$253.37M2.057.74 million shs3.96 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBRXForte Biosciences+0.45%-1.87%+14.98%+10.72%+39.87%INZYInozyme Pharma0.00%0.00%0.00%+0.50%-27.80%SCPHscPharmaceuticals+0.18%-0.36%+6.58%+33.74%+8.25%VORVor Biopharma+3.55%-1.92%-2.86%+792.00%+133.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFBRXForte Biosciences3.4262 of 5 stars3.55.00.00.03.01.70.6INZYInozyme Pharma1.43 of 5 stars3.20.00.00.00.62.50.0SCPHscPharmaceuticals3.9129 of 5 stars3.03.00.04.22.11.70.6VORVor Biopharma1.9668 of 5 stars3.30.00.00.00.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFBRXForte Biosciences 3.00Buy$68.00514.27% UpsideINZYInozyme Pharma 2.44Hold$11.75193.75% UpsideSCPHscPharmaceuticals 2.00Hold$7.7841.00% UpsideVORVor Biopharma 2.56Moderate Buy$6.07203.33% UpsideCurrent Analyst Ratings BreakdownLatest FBRX, SCPH, INZY, and VOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$5.358/25/2025SCPHscPharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.008/25/2025SCPHscPharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold8/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.008/15/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$61.008/14/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.006/30/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.006/26/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Outperform6/24/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$61.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFBRXForte BiosciencesN/AN/AN/AN/A$7.93 per shareN/AINZYInozyme PharmaN/AN/AN/AN/A$0.90 per shareN/ASCPHscPharmaceuticals$49.97M5.89N/AN/A($0.40) per share-13.80VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFBRXForte Biosciences-$35.48M-$16.29N/AN/AN/AN/A-85.38%-72.34%11/13/2025 (Estimated)INZYInozyme Pharma-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%N/ASCPHscPharmaceuticals-$85.15M-$1.81N/AN/AN/A-183.55%-1,647.86%-71.76%11/12/2025 (Estimated)VORVor BiopharmaN/A-$13.66N/AN/AN/AN/AN/AN/AN/ALatest FBRX, SCPH, INZY, and VOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FBRXForte Biosciences-$1.21-$0.96+$0.25-$0.96N/AN/A8/7/2025Q2 2025SCPHscPharmaceuticals-$0.30-$0.34-$0.04-$0.34$15.41 million$16.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFBRXForte BiosciencesN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFBRXForte BiosciencesN/A11.7411.74INZYInozyme Pharma0.652.192.19SCPHscPharmaceuticals3.863.853.14VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFBRXForte Biosciences77.63%INZYInozyme Pharma88.30%SCPHscPharmaceuticals89.52%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipFBRXForte Biosciences5.90%INZYInozyme Pharma12.18%SCPHscPharmaceuticals4.78%VORVor Biopharma0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFBRXForte Biosciences512.43 million11.70 millionOptionableINZYInozyme Pharma5064.56 million56.70 millionOptionableSCPHscPharmaceuticals3053.30 million50.75 millionOptionableVORVor Biopharma140126.68 million65.45 millionNot OptionableFBRX, SCPH, INZY, and VOR HeadlinesRecent News About These CompaniesVor Bio Appoints Adi Osovsky, S.J.D. as General CounselSeptember 2 at 8:00 AM | globenewswire.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 806,351 SharesSeptember 1 at 4:19 AM | americanbankingnews.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 611,647 Shares of StockAugust 30, 2025 | insidertrades.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,190 SharesAugust 28, 2025 | insidertrades.comVor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpointAugust 28, 2025 | msn.comTelitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA NephropathyAugust 27, 2025 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Receives $6.07 Average PT from BrokeragesAugust 27, 2025 | americanbankingnews.comVor Bio to Participate in Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 26, 2025 | marketbeat.comVor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 19, 2025 | finanznachrichten.deQ3 EPS Estimates for Vor Biopharma Reduced by HC WainwrightAugust 19, 2025 | marketbeat.comVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 18, 2025 | globenewswire.comAnalysts Set Expectations for Vor Biopharma FY2028 EarningsAugust 17, 2025 | marketbeat.comWedbush Brokers Boost Earnings Estimates for Vor BiopharmaAugust 17, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Receives "Buy" Rating from HC WainwrightAugust 16, 2025 | marketbeat.comVor Biopharma Shares Soar on Positive Results for Autoimmune-Disorder TreatmentAugust 13, 2025 | marketwatch.comVor says drug licensed from RemeGen succeeded in Sjögren’s studyAugust 13, 2025 | finance.yahoo.comVor Bio Rallies On Strong Data For Autoimmune Drug CandidateAugust 13, 2025 | benzinga.comTelitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL InhibitorAugust 13, 2025 | globenewswire.comVor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial OfficerAugust 4, 2025 | globenewswire.comVor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to BoardJuly 29, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBRX, SCPH, INZY, and VOR Company DescriptionsForte Biosciences NASDAQ:FBRX$11.07 +0.02 (+0.18%) Closing price 04:00 PM EasternExtended Trading$11.09 +0.02 (+0.18%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Inozyme Pharma NASDAQ:INZYInozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.scPharmaceuticals NASDAQ:SCPH$5.52 +0.01 (+0.18%) Closing price 04:00 PM EasternExtended Trading$5.52 0.00 (-0.09%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Vor Biopharma NYSE:VOR$2.00 -0.04 (-1.96%) Closing price 04:00 PM EasternExtended Trading$2.01 +0.01 (+0.50%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
